JP2016502538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502538A5 JP2016502538A5 JP2015545194A JP2015545194A JP2016502538A5 JP 2016502538 A5 JP2016502538 A5 JP 2016502538A5 JP 2015545194 A JP2015545194 A JP 2015545194A JP 2015545194 A JP2015545194 A JP 2015545194A JP 2016502538 A5 JP2016502538 A5 JP 2016502538A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- compound according
- conr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 5
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 claims 5
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- -1 hydrate Chemical class 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- ONIMSZJFFFNZHA-UHFFFAOYSA-N O=C(c(nc1)n[n]1-c1ccccc1)NC(CC1)CN1c1ncc[n]2c1ncc2 Chemical compound O=C(c(nc1)n[n]1-c1ccccc1)NC(CC1)CN1c1ncc[n]2c1ncc2 ONIMSZJFFFNZHA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731463P | 2012-11-29 | 2012-11-29 | |
| US61/731,463 | 2012-11-29 | ||
| PCT/US2013/072067 WO2014085490A1 (en) | 2012-11-29 | 2013-11-26 | Cxcr7 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502538A JP2016502538A (ja) | 2016-01-28 |
| JP2016502538A5 true JP2016502538A5 (https=) | 2016-12-22 |
| JP6272897B2 JP6272897B2 (ja) | 2018-01-31 |
Family
ID=50825654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545194A Active JP6272897B2 (ja) | 2012-11-29 | 2013-11-26 | Ｃｘｃｒ７アンタゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9169261B2 (https=) |
| EP (1) | EP2925745B1 (https=) |
| JP (1) | JP6272897B2 (https=) |
| KR (1) | KR102196374B1 (https=) |
| CN (1) | CN105189484B (https=) |
| AU (1) | AU2013352304C1 (https=) |
| BR (1) | BR112015012366A8 (https=) |
| CA (1) | CA2892042C (https=) |
| DK (1) | DK2925745T3 (https=) |
| ES (1) | ES2681593T3 (https=) |
| IL (1) | IL238974B (https=) |
| MX (1) | MX359651B (https=) |
| PT (1) | PT2925745T (https=) |
| RU (1) | RU2649004C2 (https=) |
| SG (1) | SG11201504212WA (https=) |
| WO (1) | WO2014085490A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359651B (es) | 2012-11-29 | 2018-10-05 | Chemocentryx Inc | Antagonistas de cxcr7. |
| WO2016040508A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| BR112017018119B1 (pt) | 2015-02-24 | 2021-11-03 | Bayer Cropscience Aktiengesellschaft | Processo para a preparação de triazóis |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| MA45782B1 (fr) * | 2016-07-28 | 2021-12-31 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| JP7240319B2 (ja) * | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| EP3713934B1 (en) | 2017-11-23 | 2022-04-13 | Universita' degli Studi di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| WO2019145460A1 (en) * | 2018-01-26 | 2019-08-01 | Idorsia Pharmaceuticals Ltd | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
| CN108794484B (zh) * | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用 |
| MX2021006915A (es) | 2018-12-12 | 2021-08-24 | Chemocentryx Inc | Inhibidores de cxcr7 para el tratamiento de cancer. |
| CN110013483B (zh) * | 2019-05-10 | 2022-04-15 | 江苏师范大学 | 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途 |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| ES3064674T3 (en) | 2019-10-16 | 2026-04-28 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
| TWI879949B (zh) | 2020-04-27 | 2025-04-11 | 南韓商奧土擇破利悟股份有限公司 | 用於ｕｂｒ盒結構域配體之化合物、組成物以及醫藥組成物 |
| CN113105469B (zh) * | 2021-04-13 | 2022-04-22 | 中国科学院新疆理化技术研究所 | 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途 |
| EP4326257A4 (en) * | 2021-04-19 | 2025-03-12 | ChemoCentryx, Inc. | AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS |
| WO2024042480A1 (en) | 2022-08-26 | 2024-02-29 | Suven Life Sciences Limited | Heteroaromatic compounds for the treatment of neurological disorders |
| PY24116080A (es) | 2024-01-03 | 2025-08-04 | Pi Industries Ltd | Amidas heterociclicas biciclicas para combatir hongos fitopatógenos |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4966691A (https=) | 1972-10-30 | 1974-06-27 | ||
| JP3989554B2 (ja) | 1996-03-29 | 2007-10-10 | デユフアー・インターナシヨナル・リサーチ・ベー・ブイ | ピペラジンおよびピペリジン化合物 |
| ES2215420T3 (es) * | 1998-12-31 | 2004-10-01 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Inhibidores de la prenil-transferasa. |
| DE60007745T2 (de) * | 1999-06-30 | 2005-03-10 | Bristol-Myers Squibb Co. | Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe |
| EP1301484A2 (en) | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
| ME00502B (me) | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| CA2448080A1 (en) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| MXPA04008797A (es) | 2002-03-13 | 2004-11-26 | Janssen Pharmaceutica Nv | Inhibidores de histona desacetilasa. |
| WO2004009587A1 (en) | 2002-07-22 | 2004-01-29 | Orchid Chemicals & Pharmaceuticals Ltd | Oxazolidinone derivatives as antibacterial agents |
| JP2004203871A (ja) | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
| WO2005023771A1 (ja) | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| WO2005074645A2 (en) | 2004-02-03 | 2005-08-18 | Chemocentryx, Inc. | Methods and compositions for modulating angiogenesis |
| AU2006230674A1 (en) | 2004-03-18 | 2006-11-16 | The Brigham And Women's Hospital, Inc. | Methods for the Treatment of Synucleinopathies |
| EP1637529A1 (en) | 2004-09-20 | 2006-03-22 | 4Sc Ag | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| WO2006038989A1 (en) * | 2004-09-29 | 2006-04-13 | Chemocentryx, Inc. | Substituted arylamides |
| WO2006100461A1 (en) | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY |
| AU2006263657A1 (en) * | 2005-06-29 | 2007-01-04 | Chemocentryx, Inc. | Substituted N-cinnamyl benzamides |
| DK1954274T3 (da) * | 2005-11-10 | 2011-01-31 | Chemocentryx Inc | Substituerede quinoloner og fremgangsmåder til anvendelse |
| WO2007111275A1 (ja) | 2006-03-24 | 2007-10-04 | The University Of Tokyo | シグナル伝達阻害方法、それに用いるシグナル伝達阻害剤およびその用途 |
| EP2001485B1 (en) | 2006-03-29 | 2015-09-09 | Merck Sharp & Dohme Corp. | Diazepan orexin receptor antagonists |
| WO2007115232A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| US20090192143A1 (en) | 2006-07-14 | 2009-07-30 | Cox Christopher D | Substituted diazepan orexin receptor antagonists |
| BRPI0714440A2 (pt) | 2006-07-21 | 2013-04-24 | Irm Llc | composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica |
| WO2008020229A2 (en) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
| US8088895B2 (en) * | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| US20080293711A1 (en) | 2007-03-08 | 2008-11-27 | Clark Michael P | Chemokine receptor modulators |
| TW200944523A (en) | 2008-02-08 | 2009-11-01 | Organon Nv | (Dihydro)pyrrolo[2,1-a]isoquinolines |
| CA2742515C (en) | 2008-11-04 | 2017-07-11 | Chemocentryx, Inc. | 1,4-diazepane modulators of cxcr7 |
| US8853202B2 (en) | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
| US20110014121A1 (en) | 2008-11-04 | 2011-01-20 | Chemocentryx, Inc. | Modulators of cxcr7 |
| GB0822981D0 (en) * | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| KR101541086B1 (ko) * | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| CN102372717B (zh) * | 2010-08-20 | 2014-06-18 | 和记黄埔医药（上海）有限公司 | 吡咯并嘧啶类化合物及其用途 |
| EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| MX359651B (es) | 2012-11-29 | 2018-10-05 | Chemocentryx Inc | Antagonistas de cxcr7. |
| US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| MX2021006915A (es) | 2018-12-12 | 2021-08-24 | Chemocentryx Inc | Inhibidores de cxcr7 para el tratamiento de cancer. |
-
2013
- 2013-11-26 MX MX2015006412A patent/MX359651B/es active IP Right Grant
- 2013-11-26 CA CA2892042A patent/CA2892042C/en active Active
- 2013-11-26 KR KR1020157017200A patent/KR102196374B1/ko active Active
- 2013-11-26 WO PCT/US2013/072067 patent/WO2014085490A1/en not_active Ceased
- 2013-11-26 ES ES13859147.4T patent/ES2681593T3/es active Active
- 2013-11-26 AU AU2013352304A patent/AU2013352304C1/en active Active
- 2013-11-26 BR BR112015012366A patent/BR112015012366A8/pt not_active Application Discontinuation
- 2013-11-26 CN CN201380062708.3A patent/CN105189484B/zh active Active
- 2013-11-26 RU RU2015125544A patent/RU2649004C2/ru active
- 2013-11-26 DK DK13859147.4T patent/DK2925745T3/en active
- 2013-11-26 PT PT138591474T patent/PT2925745T/pt unknown
- 2013-11-26 SG SG11201504212WA patent/SG11201504212WA/en unknown
- 2013-11-26 JP JP2015545194A patent/JP6272897B2/ja active Active
- 2013-11-26 EP EP13859147.4A patent/EP2925745B1/en active Active
- 2013-11-27 US US14/091,641 patent/US9169261B2/en active Active
-
2015
- 2015-05-21 IL IL238974A patent/IL238974B/en active IP Right Grant
- 2015-08-26 US US14/836,172 patent/US9783544B2/en active Active
-
2017
- 2017-08-31 US US15/692,739 patent/US10287292B2/en active Active
-
2019
- 2019-04-09 US US16/379,599 patent/US11059825B2/en active Active
-
2021
- 2021-05-27 US US17/331,750 patent/US11834452B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502538A5 (https=) | ||
| RU2015125544A (ru) | Антагонисты cxcr7 | |
| JP5211183B2 (ja) | ３−置換−２（アリールアルキル）−１−アザビシクロアルカンおよびこれらの使用方法 | |
| Harris et al. | Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors | |
| JP5739398B2 (ja) | ニコチン性アセチルコリン受容体サブタイプ選択的なジアザビシクロアルカンのアミド | |
| Bernard-Gauthier et al. | Identification of [18F] TRACK, a fluorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging | |
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| ES2739973T3 (es) | Inhibidores de PDE10 radiomarcados | |
| Liu et al. | [11C] CHDI-626, a PET tracer candidate for imaging mutant Huntingtin aggregates with reduced binding to AD pathological proteins | |
| JP2017514806A5 (https=) | ||
| Kassenbrock et al. | Selected PET radioligands for ion channel linked neuroreceptor imaging: focus on GABA, NMDA and nACh receptors | |
| US20100197720A1 (en) | Heteroaryl-substituted diazatricycloalkanes and methods of use thereof | |
| IL303333A (en) | Alc1 inhibitors and synergy with parpi | |
| An et al. | DNA compatible intermolecular wittig olefination for the construction of α, β-unsaturated carbonyl compounds | |
| Li et al. | Discovery of (S)-N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino) methyl) phenyl)-6-oxopyridazin-1 (6 H)-yl) ethyl) benzamide as potent class I selective HDAC inhibitor for oral anticancer drug candidate | |
| Wu et al. | In vivo positron emission tomography (PET) imaging of mesenchymal− epithelial transition (MET) receptor | |
| JP2008534541A5 (https=) | ||
| Gourand et al. | Chemical delivery system of MIBG to the central nervous system: synthesis, 11C-radiosynthesis, and in vivo evaluation | |
| CN110088098A (zh) | 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途 | |
| Fang et al. | Preclinical evaluation of 131I/18F-labeled covalent small-molecule inhibitors for STING status imaging | |
| Zha et al. | Targeting colony‐stimulating factor 1 receptor: From therapeutic drugs to diagnostic radiotracers | |
| JP2013525455A5 (https=) | ||
| Qiu et al. | Rational design, synthesis, and biological evaluation of novel c-Met degraders for lung cancer therapy | |
| Fuchigami et al. | Synthesis and evaluation of a radioiodinated 4, 6-diaryl-3-cyano-2-pyridinone derivative as a survivin targeting SPECT probe for tumor imaging | |
| Wang et al. | Development and Evaluation of [11C] I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging |